EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Sodium-Glucose Cotransporter-2 inhibitor (SGLT2i) Prescription Rates Amongst Diabetologists for Type 2 Diabetes Patients with Albuminuric Diabetic Kidney Disease:

Peachaphol Chongvoranond, Yotsapon Thewjitcharoen, Waralee Chatchomchaun, Ekgaluck Wanothayaroj, Siriwan Butadej, Soontaree Nakasatien, Sirinate Krittiyawong, Thep Himathongkam

Journal of the ASEAN Federation of Endocrine Societies · 13.11.2025 · 40 (2) · 69-77

DOI: 10.15605/jafes.040.02.22 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the ASEAN Federation of Endocrine Societies, online erschienen am 13.11.2025. Verfasst von Peachaphol Chongvoranond und 7 weiteren Autor:innen. Beteiligte Einrichtung: Diabetes, Thyroid, and Endocrine Center, Vimut-Theptarin Hospital, Bangkok, Thailand. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Albuminuria. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Despite the beneficial effects of SGLT2i in reducing kidney disease progression and mortality in people with diabetic kidney disease (DKD), the use of SGLT2i in this population remains low.

Objective

To explore the prescription rates of SGLT2i in type 2 diabetes (T2D) patients with albuminuric DKD and to assessclinician-perceived barriers to prescribing SGLT2i.Methodology. A retrospective study of all medical records of T2D patients with albuminuric DKD and eGFR ≥20 ml/min/1.73 m2 in 2023 who had been treated by 13 diabetologists was conducted at Vimut-Theptarin Hospital, a private tertiary diabetes center in Bangkok. In cases of no documentation of non-prescribed SGLT2i, treating physicians were contacted to explore the reasons.

Result

A total of 282 medical records were reviewed (mean age 65.9 ± 10.0 years, A1C 7.5 ± 1.2 %, duration of diabetes 19.7 ± 10.4 years, mean eGFR 68.3 ± 24.1 mL/min/1.73 m2, median UACR 151 (IQR 309) mg/g Cr, RAS inhibitors usage 80.1%). The SGLT2i prescription rate was 58.9% in 2023. Coronary artery disease, age ≥65 years, eGFR

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsDiabetes Mellitus, Type 2Diabetic NephropathiesAlbuminuriaPractice Patterns, Physicians'HumansMaleFemaleAgedRetrospective StudiesMiddle AgedThailand

Stichwörter der Autor:innen

Thaidiabetic kidney diseaseprescription ratesreal-world datasodium-glucose cotransporter 2 inhibitors (SGLT2i)

Substanzen

Sodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Diabetes, Thyroid, and Endocrine Center, Vimut-Theptarin Hospital, Bangkok, Thailand.

Zitieren

APA

Chongvoranond, P., Thewjitcharoen, Y., Chatchomchaun, W., Wanothayaroj, E., Butadej, S., Nakasatien, S., Krittiyawong, S., & Himathongkam, T. (2025). Sodium-Glucose Cotransporter-2 inhibitor (SGLT2i) Prescription Rates Amongst Diabetologists for Type 2 Diabetes Patients with Albuminuric Diabetic Kidney Disease:. Journal of the ASEAN Federation of Endocrine Societies, 40(2), 69-77. https://doi.org/10.15605/jafes.040.02.22

Vancouver

Chongvoranond P, Thewjitcharoen Y, Chatchomchaun W, Wanothayaroj E, Butadej S, Nakasatien S, et al. Sodium-Glucose Cotransporter-2 inhibitor (SGLT2i) Prescription Rates Amongst Diabetologists for Type 2 Diabetes Patients with Albuminuric Diabetic Kidney Disease:. Journal of the ASEAN Federation of Endocrine Societies. 2025;40(2):69-77. doi:10.15605/jafes.040.02.22

BibTeX
@article{Chongvoranond2025,
  author = {Chongvoranond, Peachaphol and Thewjitcharoen, Yotsapon and Chatchomchaun, Waralee and Wanothayaroj, Ekgaluck and Butadej, Siriwan and Nakasatien, Soontaree and Krittiyawong, Sirinate and Himathongkam, Thep},
  title = {Sodium-Glucose Cotransporter-2 inhibitor (SGLT2i) Prescription Rates Amongst Diabetologists for Type 2 Diabetes Patients with Albuminuric Diabetic Kidney Disease:},
  journal = {Journal of the ASEAN Federation of Endocrine Societies},
  year = {2025},
  volume = {40},
  number = {2},
  pages = {69--77},
  doi = {10.15605/jafes.040.02.22}
}
Kostenlos starten →